DRP® Validation

Our proprietary DRP® technology has been validated in multiple clinical studies, including those listed below.  These include a 135-patient study demonstrating prediction of efficacy of epirubicin/doxorubicin in metastatic breast cancer patients as well as a recent Phase 1 study with our PARPi, 2X-121.


Cancer Type


2X-121 Multiple cancer types including ovarian and pancreatic 2X Oncology Announces Validation of DRP for its PARP Inhibitor 2X-121; Developed DRP Successfully Identified Responders and Non-responders to Treatment with 2X-121 in 13-Patient Blinded Study (09 Aug 2017 Press release)
Epirubicin Metastatic breast cancer Buhl AS et al. Retrospective-prospective blinded evaluation predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort. J Clin Oncol 35, 2017 (suppl; abstr 1071). View abstract.




Advanced breast cancer DRP Successfully Predicts Effect of 4 Breast Cancer Drugs for Personalized Medicine (24 Jan 2017 Press release)



Gastroesophageal cancer Winther M, Knudsen S et al. (2016) Clinical Impact of a Novel MicroRNA Chemo-Sensitivity Predictor in Gastrooesophageal Cancer. PLoS ONE 11(2): e0148070.
Belinostat Acute myeloid leukemia (AML) Bullinger L, Knudsen S et al. Results of a phase I/II trial of belinostat in combination with idarubicin in AML – favorable impact on mainly intermediate cytogenetic risk AML can be predicted by gene expression profiling. (poster presented at ESMO 2012)
Adjuvant Cisplatin and Vinorelbine Non-small cell lung cancer (NSCLC) Buhl IK et al. Multigene expression profile for predicting efficacy of cisplatin and vinorelbine in non-small cell lung cancer. Annals of Oncology (2016) 27 (6): 411-415. (abstr 1187P).
Fulvestrant Breast cancer Knudsen S, Jensen T et al. (2014) Development and Validation of a Gene Expression Score That Predicts Response to Fulvestrant in Breast Cancer Patients. PLoS ONE 9(2): e87415.
CHOP and CHOEP (including doxorubicin) Diffuse large B-cell lymphoma Knudsen S, Hother C et al. (2015). Development and Blind Clinical Validation of a MicroRNA Based Predictor of Response to Treatment with R-CHO(E)P in DLBCL. PLoS ONE, 10(2), e0115538. 

DRP® is a trademark of  Medical Prognosis Institute A/S.